In recent years, the Spanish drug agency, AEMPS, and the “Interministerial Commission on Prices of Medicines and Health Products” have undergone a major reform. Read more...

During these last weeks of 2018, we have been digging deeply into the issue of market access for future market entrants in the field of Alzheimers’ Disease. Read more...

There was a time when market access and pricing research was simply called “payer research”.

When we are asked to conduct strategic research on market access, we are typically asked to cover EU5 and USA.

Almost 2 years after the launch of EMA’s PRIority MEdicines scheme (PRIME), 31 compounds have been accepted so far.  PRIME status means more than fast, conditional or adaptive approval.

A long history low drug prices in Italy have given Italy’s central pricing and reimbursement body AIFA a bad reputation with industry.

Our business at AX’S Consulting in 2017 confirms our impression of the previous years: “value stories” are no longer fashionable! Global market access is no longer interested in value stories.